Glioblastoma is an aggressive brain tumor that affects an estimated 12,000 people per year, with poor overall prognosis and long-term survival rates. Northwestern Medicine scientists are at the forefront of leading-edge investigations to discover the roots of glioblastoma’s origins, and to pinpoint innovative new treatments to attack this deadly disease.
Northwestern investigators have developed a novel vaccine that utilizes a specialized group of B-cells to promote anti-tumor immunity against glioblastoma.
Measuring epigenetic signatures in blood plasma could help classify brain tumors, according to a study published in Nature Medicine.
The elevated expression of a gene called LY6K was correlated with increased cancer cell growth and resistance to radiation therapy in glioblastoma, according to a recent Northwestern Medicine study.
A previously unknown migration of glioblastoma may explain why current treatments stall out over time, according to a new study.
A new lipid nanoparticle drug helped make tumor cells more vulnerable to therapy, significantly prolonging survival in models of glioblastoma.
A recent Northwestern Medicine study found that patients with glioblastoma responded better or worse to immunotherapy depending on the presence of certain mutations in their tumors.
A Northwestern Medicine study has demonstrated the role of dopamine in the progression of glioblastoma and suggests that targeting the neurotransmitter may slow cancer growth.